Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
Purple Biotech's IM1240 abstract was accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium, a notable distinction for the lead tri-specific antibody from its CAPTN-3 platform. The data will be presented in Plenary Session 7 on November 20, 2026, by Amir Horowitz, Ph.D., of the Icahn School of Medicine at Mount Sinai.
Key figures
- Abstract Number
- ENA26-0137
- Presentation Date
- 2026-11-20T15:00:00+01:00
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.